Dysregulation of tyrosine kinases and use of imatinib in small animal practice

Veterinary Journal

Volumn 205, Issue 2, 2015, Pages 180-188

  Bonkobara, Makoto ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

Author keywords

Canine; Feline; Imatinib; KIT mutations; Mast cell tumours

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; BCL ABL GENE; BLOOD TOXICITY; CANCER INHIBITION; CAT; DOG; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANCE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME REGULATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIT GENE; LETHARGY; LOW DRUG DOSE; LYMPHOMA; MASTOCYTOMA; MELANOMA; MUTATION RATE; NEUTROPENIA; NONHUMAN; PDGFR GENE; PERSONALIZED MEDICINE; PROTEINURIA; PULMONARY HYPERTENSION; REVIEW; VOMITING; ANIMAL; CAT DISEASES; DOG DISEASES; GENETICS; METABOLISM; NEOPLASMS; VETERINARY;

ANIMALIA; CANIS FAMILIARIS; FELIDAE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAT DISEASES; CATS; DOG DISEASES; DOGS; IMATINIB MESYLATE; NEOPLASMS; SRC-FAMILY KINASES;

EID: 84937525447     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2014.12.015     Document Type: Review

References (87)

1. Abou Asa S., Mori T., Maruo K., Khater A., El-Sawak A., Abd El-Aziz E., Yanai T., Sakai H. Analysis of genomic mutation and immunohistochemistry of platelet-derived growth factor receptors in canine vascular tumours. Veterinary and Comparative Oncology 2013, 10.1111/vco.12035.
2. Amagai Y., Tanaka A., Matsuda A., Jung K., Oida K., Nishikawa S., Jang H., Matsuda H. Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours. Journal of Small Animal Practice 2013, 54:377-380.
3. Aricò A., Guadagnin E., Ferraresso S., Gelain M.E., Iussich S., Rütgen B.C., Mazzariol S., Marconato L., Aresu L. Platelet-derived growth factors and receptors in canine lymphoma. Journal of Comparative Pathology 2014, 151:322-328.
4. Arita S., Arita N., Hikasa Y. Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs. Canadian Veterinary Journal 2013, 54:255-261.
5. Asa S.A., Murai A., Murakami M., Hoshino Y., Mori T., Maruo K., Khater A., El-Sawak A., el Aziz E.A., Yanai T., et al. Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma. Histology and Histopathology 2012, 27:601-607.
6. Backlund B., Cianciolo R.E., Cook A.K., Clubb F.J., Lees G.E. Minimal change glomerulopathy in a cat. Journal of Feline Medicine and Surgery 2011, 13:291-295.
7. Beadling C., Jacobson-Dunlop E., Hodi F.S., Le C., Warrick A., Patterson J., Town A., Harlow A., Cruz F., Azar S., et al. KIT gene mutations and copy number in melanoma subtypes. Clinical Cancer Research 2008, 14:6821-6828.
8. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
9. Breen M., Modiano J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans - Man and his best friend share more than companionship. Chromosome Research 2008, 16:145-154.
10. Brown R.J., Newman S.J., Durtschi D.C., Leblanc A.K. Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry. Veterinary and Comparative Oncology 2012, 10:74-79.
11. Brunetti B., Beha G., Benazzi C., Bondin V., De Tolla L., Sarli G. CD117 Expression influences proliferation but not survival in canine mammary tumours. Journal of Comparative Pathology 2014, 151:202-206.
12. Chu P.Y., Pan S.L., Liu C.H., Lee J., Yeh L.S., Liao A.T. KIT gene exon 11 mutations in canine malignant melanoma. The Veterinary Journal 2013, 196:226-230.
13. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine 2003, 348:1201-1214.
14. Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumours: Origin and molecular oncology. Nature Reviews. Cancer 2011, 11:865-878.
15. Cruz Cardona J.A., Milner R., Alleman A.R., Williams C., Vernau W., Breen M., Tompkins M. BCR-ABL translocation in a dog with chronic monocytic leukemia. Veterinary Clinical Pathology 2011, 40:40-47.
16. Culver S., Ito D., Borst L., Bell J.S., Modiano J.F., Breen M. Molecular characterization of canine BCR-ABL-positive chronic myelomonocytic leukemia before and after chemotherapy. Veterinary Clinical Pathology 2013, 42:314-322.
17. Dank G., Chien M.B., London C.A. Activating mutations in the catalytic or juxtamembrane domain of c-Kit in splenic mast cell tumors of cats. American Journal of Veterinary Research 2002, 63:1129-1133.
18. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., Dimitrijevic S., Sciot R., Stul M., Vranck H., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer 2004, 40:689-695.
19. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
20. Dewar A.L., Cambareri A.C., Zannettino A.C., Miller B.L., Doherty K.V., Hughes T.P., Lyons A.B. Macrophage colony-stimulating factor receptor Cfms is a novel target of imatinib. Blood 2005, 105:3127-3132.
21. Dickerson E.B., Marley K., Edris W., Tyner J.W., Schalk V., Macdonald V., Loriaux M., Druker B.J., Helfand S.C. Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-β and Src in tumor growth. Translational Oncology 2013, 6:158-168.
22. Downing S., Chien M.B., Kass P.H., Moore P.E., London C.A. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. American Journal of Veterinary Research 2002, 63:1718-1723.
23. Druker B.J., Lydon N.B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Journal of Clinical Investigation 2000, 105:3-7.
24. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996, 2:561-566.
25. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 2001, 344:1031-1037.
26. Figueiredo J.F., Culver S., Behling-Kelly E., Breen M., Friedrichs K.R. Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog. Veterinary Clinical Pathology 2012, 41:362-368.
27. Foster R., Griffith R., Ferrao P., Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. Journal of Molecular Graphics and Modelling 2004, 23:139-152.
28. Frost D., Lasota J., Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: A histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Veterinary Pathology 2003, 40:42-54.
29. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., Sanchez M.L., Nunez R., Prados A., Aldanondo I., Sanchez L., Dominguez M., Botana L.M., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
30. Giantin M., Aresu L., Aricò A., Gelain M.E., Riondato F., Martini V., Comazzi S., Dacasto M. Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: Might c-KIT represent a therapeutic target?. Veterinary Immunology and Immunopathology 2013, 152:325-332.
31. Giantin M., Aresu L., Aricò A., Gelain M.E., Riondato F., Comazzi S., Dacasto M. Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: Might c-kit represent a therapeutic target?. Veterinary Immunology and Immunopathology 2013, 154:153-159.
32. Gil da Costa R.M., Matos E., Rema A., Lopes C., Pires M.A., Gärtner F. CD117 immunoexpression in canine mast cell tumours: Correlations with pathological variables and proliferation markers. BMC Veterinary Research 2007, 3:19.
33. Gregory-Bryson E., Bartlett E., Kiupel M., Hayes S., Yuzbasiyan-Gurkan V. Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. BMC Cancer 2010, 10:559.
34. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
35. Hara S., Morita R., Shiraki A., Segawa R., Ogawa T., Takimoto N., Suzuki K., Nomura K., Shibutani M. Expression of protein gene product 9.5 and Sal-like protein 4 in canine seminomas. Journal of Comparative Pathology 2014, 151:10-18.
36. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology 2003, 21:4342-4349.
37. Heinrich M.C., Maki R.G., Corless C.L., Antonescu C.R., Harlow A., Griffith D., Town A., McKinley A., Ou W.B., Fletcher J.A., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib inimatinib-resistant gastrointestinal stromal tumor. Journal of Clinical Oncology 2008, 26:5352-5359.
38. Higgins R.J., Dickinson P.J., LeCouteur R.A., Bollen A.W., Wang H., Wang H., Corely L.J., Moore L.M., Zang W., Fuller G.N. Spontaneous canine gliomas: Overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. Journal of Neuro-Oncology 2010, 98:49-55.
39. Hodi F.S., Corless C.L., Giobbie-Hurder A., Fletcher J.A., Zhu M., Marino-Enriquez A., Friedlander P., Gonzalez R., Weber J.S., Gajewski T.F., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Journal of Clinical Oncology 2013, 31:3182-3190.
40. Isotani M., Tamura K., Yagihara H., Hikosaka M., Ono K., Washizu T., Bonkobara M. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Veterinary Immunology and Immunopathology 2006, 114:168-172.
41. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 2008, 22:985-988.
42. Isotani M., Yamada O., Lachowicz J.L., Tamura K., Yagihara H., Fujino Y., Ono K., Washizu T., Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. British Journal of Haematology 2010, 148:144-153.
43. Ito K., Kobayashi M., Kuroki S., Sasaki Y., Iwata T., Mori K., Kuroki T., Ozawa Y., Tetsuka M., Nakagawa T., et al. The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo. The Veterinary Journal 2013, 198:577-582.
44. Katayama R., Huelsmeyer M.K., Marr A.K., Kurzman I.D., Thamm D.H., Vail D.M. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemotherapy and Pharmacology 2004, 54:25-33.
45. Kobayashi M., Sugisaki O., Ishii N., Yamada O., Ito K., Kuroki S., Sasaki Y., Ono K., Washizu T., Bonkobara M. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. The Veterinary Journal 2012, 193:264-267.
46. Kobayashi M., Kuroki S., Ito K., Yasuda A., Sawada H., Ono K., Washizu T., Bonkobara M. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation. The Veterinary Journal 2013, 198:271-274.
47. Kubo K., Matsuyama S., Katayama K., Tsutsumi C., Yonezawa K., Shimada T., Kotani T., Sakuma S., Ohashi F., Takamori Y. Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor. The Journal of Veterinary Medical Science 1998, 60:1335-1340.
48. Lachowicz J.L., Post G.S., Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. Journal of Veterinary Internal Medicine 2005, 19:860-864.
49. Lahortiga I., Akin C., Cools J., Wilson T.M., Mentens N., Arthur D.C., Maric I., Noel P., Kocabas C., Marynen P., et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008, 93:49-56.
50. Lasota J., Jasinski M., Sarlomo-Rikala M., Miettinen M. C-kit mutations occur preferentially in malignant versus benign GISTs and do not occur in leiomyomas and leiomyosarcomas. American Journal of Pathology 1999, 154:53-60.
51. Letard S., Yang Y., Hanssens K., Palmérini F., Leventhal P.S., Guéry S., Moussy A., Kinet J.P., Hermine O., Dubreuil P. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Molecular Cancer Research 2008, 6:1137-1145.
52. Liao A.T., Chien M.B., Shenoy N., Mendel D.B., McMahon G., Cherrington J.M., London C.A. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100:585-593.
53. London C.A., Kisseberth W.C., Galli S.J., Geissler E.N., Helfand S.C. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. Journal of Comparative Pathology 1996, 115:399-414.
54. London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology 1999, 27:689-697.
55. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
56. Ma Y., Longley B.J., Wang X., Blount J.L., Langley K., Caughey G.H. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. Journal of Investigative Dermatology 1999, 112:165-170.
57. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H., McMahon G., Longley B.J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99:1741-1744.
58. Maniscalco L., Iussich S., Morello E., Martano M., Biolatti B., Riondato F., Della Salda L., Romanucci M., Malatesta D., Bongiovanni L., et al. PDGFs and PDGFRs in canine osteosarcoma: New targets for innovative therapeutic strategies in comparative oncology. The Veterinary Journal 2013, 195:41-47.
59. Manley P.W., Stiefl N., Cowan-Jacob S.W., Kaufman S., Mestan J., Wartmann M., Wiesmann M., Woodman R., Gallagher N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorganic and Medicinal Chemistry 2010, 18:6977-6986.
60. Marconato L., Bettini G., Giacoboni C., Romanelli G., Cesari A., Zatelli A., Zini E. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. Journal of Veterinary Internal Medicine 2008, 22:1001-1007.
61. Marconato L., Zorzan E., Giantin M., Di Palma S., Cancedda S., Dacasto M. Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline. Journal of Veterinary Internal Medicine 2014, 28:547-553.
62. Morini M., Bettini G., Preziosi R., Mandrioli L. C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. Journal of Histochemistry and Cytochemistry 2004, 52:705-708.
63. Morini M., Gentilini F., Pietra M., Spadari A., Turba M.E., Mandrioli L., Bettini G. Cytological, immunohistochemical and mutational analysis of a gastric gastrointestinal stromal tumour in a cat. Journal of Comparative Pathology 2011, 145:152-157.
64. Murakami A., Mori T., Sakai H., Murakami M., Yanai T., Hoshino Y., Maruo K. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. Veterinary and Comparative Oncology 2011, 9:219-224.
65. Nakano Y., Kobayashi T., Oshima F., Fukazawa E., Yamagami T., Shiraishi Y., Takanosu M. Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11. Journal of Veterinary Medical Science 2014, 76:545-548.
66. Newman S.J., Jankovsky J.M., Rohrbach B.W., LeBlanc A.K. C-kit expression in canine mucosal melanomas. Veterinary Pathology 2012, 49:760-765.
67. Nguyen S.M., Thamm D.H., Vail D.M., London C.A. Response evaluation criteria for solid tumours in dogs (v1.0): A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2013, 10.1111/vco.12032.
68. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology 2013, 88:612-624.
69. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., Reeder T.L., Li C.Y., Cross N.C., Cools J., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096.
70. Pérez M.L., Culver S., Owen J.L., Dunbar M., Kow K., Breen M., Milner R.J. Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia. Anti-Cancer Drugs 2013, 24:1098-1103.
71. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology 2004, 22:935-942.
72. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. Journal of Clinical Investigation 2008, 118:2372-2379.
73. Rodriguez-Cariño C., Fondevila D., Segalés J., Rabanal R.M. Expression of KIT receptor in feline cutaneous mast cell tumors. Veterinary Pathology 2009, 46:878-883.
74. Sabattini S., Bettini G. An immunohistochemical analysis of canine haemangioma and haemangiosarcoma. Journal of Comparative Pathology 2009, 140:158-168.
75. Sabattini S., Bettini G. Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors. Veterinary Pathology 2010, 47:643-653.
76. Sabattini S., Guadagni Frizzon M., Gentilini F., Turba M.E., Capitani O., Bettini G. Prognostic significance of Kit receptor tyrosine kinase dysregulations in feline cutaneous mast cell tumors. Veterinary Pathology 2013, 50:797-805.
77. Smith A.J., Njaa B.L., Lamm C.G. Immunohistochemical expression of c-KIT protein in feline soft tissue fibrosarcomas. Veterinary Pathology 2009, 46:934-939.
78. Takeuchi Y., Fujino Y., Watanabe M., Takahashi M., Nakagawa T., Takeuchi A., Bonkobara M., Kobayashi T., Ohno K., Uchida K., et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: A retrospective cohort study. The Veterinary Journal 2013, 196:492-498.
79. Urie B.K., Russell D.S., Kisseberth W.C., London C.A. Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma. BMC Veterinary Research 2012, 8:67.
80. Usher S.G., Radford A.D., Villiers E.J., Blackwood L. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Experimental Hematology 2009, 37:65-77.
81. Verstovsek S. New hematological indications for imatinib. US Oncological Disease 2007, 1:36-39.
82. Veterinary Cooperative Oncology group - Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Veterinary and Comparative Oncology 2011, Veterinary Cooperative Oncology Group. 10.1111/j.1476-5829.2011.00283.x.
83. Webster J.D., Yuzbasiyan-Gurkan V., Kaneene J.B., Miller R., Resau J.H., Kiupel M. The role of c-KIT in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. Neoplasia 2006, 8:104-111.
84. Yamada O., Kobayashi M., Sugisaki O., Ishii N., Ito K., Kuroki S., Sasaki Y., Isotani M., Ono K., Washizu T., et al. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Veterinary Immunology and Immunopathology 2011, 142:101-106.
85. Zavodovskaya R., Liao A.T., Jones C.L., Yip B., Chien M.B., Moore P.F., London C.A. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. American Journal of Veterinary Research 2006, 67:633-641.
86. Zemke D., Yamini B., Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Veterinary Pathology 2002, 39:529-535.
87. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends in Molecular Medicine 2002, 8:17-23.